Your browser is no longer supported. Please, upgrade your browser.
ZIOP ZIOPHARM Oncology, Inc. daily Stock Chart
ZIOPHARM Oncology, Inc.
Index- P/E- EPS (ttm)-0.70 Insider Own7.12% Shs Outstand212.79M Perf Week11.29%
Market Cap600.63M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float200.16M Perf Month-5.48%
Income-126.60M PEG- EPS next Q-0.09 Inst Own54.90% Short Float15.66% Perf Quarter-15.60%
Sales- P/S- EPS this Y-173.40% Inst Trans3.07% Short Ratio16.69 Perf Half Y10.40%
Book/sh0.77 P/B3.58 EPS next Y-10.80% ROA-83.40% Target Price- Perf Year-38.80%
Cash/sh0.71 P/C3.91 EPS next 5Y- ROE-93.00% 52W Range1.79 - 5.61 Perf YTD-41.53%
Dividend- P/FCF- EPS past 5Y-17.40% ROI- 52W High-50.76% Beta2.25
Dividend %- Quick Ratio10.10 Sales past 5Y- Gross Margin- 52W Low53.76% ATR0.18
Employees73 Current Ratio10.10 Sales Q/Q- Oper. Margin- RSI (14)48.14 Volatility7.59% 5.98%
OptionableYes Debt/Eq0.00 EPS Q/Q3.90% Profit Margin- Rel Volume1.91 Prev Close2.82
ShortableYes LT Debt/Eq0.00 EarningsAug 06 AMC Payout- Avg Volume1.88M Price2.76
Recom2.20 SMA202.17% SMA50-7.67% SMA200-17.24% Volume3,581,772 Change-2.13%
Jun-19-20Initiated Jefferies Buy $7
Mar-04-20Initiated Cantor Fitzgerald Overweight $6
Aug-23-19Resumed Raymond James Outperform
Apr-04-19Initiated Lake Street Buy $7
Apr-01-19Initiated Laidlaw Buy $7.50
Nov-15-18Upgrade Raymond James Mkt Perform → Outperform
Jun-18-18Downgrade JP Morgan Neutral → Underweight
Jun-01-17Initiated H.C. Wainwright Buy $9.50
Aug-10-16Upgrade Wells Fargo Underperform → Market Perform
Jul-19-16Reiterated Mizuho Neutral $7 → $5
Jun-02-16Initiated Raymond James Mkt Perform
May-11-16Reiterated Mizuho Neutral $6 → $7
Jan-25-16Reiterated Mizuho Neutral $10 → $6
Dec-04-15Initiated Wells Fargo Underperform
Jun-10-15Reiterated Mizuho Neutral $14 → $10
Mar-10-15Downgrade Mizuho Buy → Neutral $14
Mar-02-15Reiterated Mizuho Buy $11 → $14
Mar-20-14Initiated Mizuho Buy $11
Apr-02-12Reiterated Griffin Securities Buy $9 → $12
Mar-26-12Initiated Canaccord Genuity Buy $9
Sep-15-20 08:30AM  
Sep-14-20 04:17PM  
Sep-10-20 09:00AM  
Sep-07-20 09:58AM  
Aug-06-20 04:04PM  
Jul-28-20 09:00AM  
Jul-22-20 08:30AM  
Jul-10-20 07:25AM  
Jul-09-20 04:15PM  
Jul-08-20 08:30AM  
Jun-30-20 11:47PM  
Jun-22-20 09:48AM  
Jun-15-20 08:33AM  
Jun-12-20 09:00AM  
May-29-20 08:00AM  
May-27-20 04:15PM  
May-11-20 02:50PM  
May-08-20 04:00PM  
May-07-20 04:05PM  
Apr-30-20 08:00AM  
Apr-27-20 08:30AM  
Apr-06-20 06:00AM  
Mar-04-20 12:37PM  
Mar-02-20 04:05PM  
Feb-28-20 08:30AM  
Feb-24-20 08:30AM  
Feb-05-20 09:03AM  
Feb-04-20 04:01PM  
Jan-30-20 08:45AM  
Dec-30-19 08:56AM  
Dec-19-19 08:45AM  
Dec-11-19 11:23AM  
Dec-09-19 05:00PM  
Dec-08-19 09:00AM  
Dec-06-19 08:00AM  
Nov-23-19 09:00AM  
Nov-19-19 03:31PM  
Nov-18-19 07:00AM  
Nov-11-19 09:10AM  
Nov-07-19 04:05PM  
Oct-30-19 08:30AM  
Oct-28-19 06:06PM  
Oct-18-19 06:00AM  
Oct-15-19 08:00AM  
Oct-11-19 12:49PM  
Oct-01-19 08:00AM  
Sep-30-19 06:45AM  
Sep-03-19 02:21PM  
Aug-28-19 04:05PM  
Aug-23-19 07:00AM  
Aug-16-19 01:40AM  
Aug-14-19 02:00PM  
Aug-09-19 02:11PM  
Aug-08-19 07:50AM  
Jul-30-19 09:15AM  
Jul-29-19 08:40AM  
Jul-25-19 06:00AM  
Jul-24-19 08:30AM  
Jul-03-19 08:30AM  
Jun-27-19 04:10PM  
Jun-26-19 08:30AM  
Jun-17-19 01:05PM  
Jun-11-19 08:00AM  
Jun-02-19 09:10AM  
May-29-19 07:38AM  
May-28-19 04:10PM  
May-23-19 04:15PM  
May-17-19 07:21PM  
May-08-19 05:19PM  
May-01-19 04:10PM  
Apr-25-19 02:45AM  
Apr-16-19 03:08PM  
Apr-01-19 10:36AM  
Mar-05-19 07:00PM  
Mar-01-19 09:16AM  
Feb-25-19 07:50AM  
Feb-21-19 08:30AM  
Feb-14-19 08:30AM  
Feb-13-19 06:49AM  
Feb-11-19 07:45AM  
Feb-01-19 07:30AM  
Jan-21-19 09:00AM  
Jan-07-19 04:01PM  
Dec-28-18 08:52AM  
Dec-27-18 01:16PM  
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells. It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor (CAR) T-cell and T-cell receptor T-cell therapies. ZIOPHARM Oncology, Inc. has license agreement with Precigen, Inc. and MD Anderson Cancer Center; collaboration with MD Anderson targeting CD19 on malignant B cells using Sleeping Beauty platform; and research and development agreement with the National Cancer Institute to evaluate autologous peripheral blood lymphocytes, and Ares Trading S.A. The company was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAUNEY DAVID M MDPresidentJan 02Sale4.5522,394101,893195,278Jan 03 05:10 PM
Lafond Kevin GSVP, Treasurer & CAOJan 02Sale4.5521,57098,14463,985Jan 03 05:09 PM
Hadfield RobertGeneral Counsel and SecretaryJan 02Sale4.5516,85376,681100,719Jan 03 05:07 PM
De Groot EleanorEVP, GM Cell TherapyJan 02Sale4.5524,890113,250174,333Jan 03 05:06 PM
Buck JillEVP, GM Gene TherapyJan 02Sale4.5527,923127,050173,710Jan 03 05:04 PM
Cooper Laurence James NeilChief Executive OfficerDec 30Sale4.88110,694540,1871,733,273Dec 31 04:37 PM
Cooper Laurence James NeilChief Executive OfficerDec 27Option Exercise2.2444,64299,9981,843,967Dec 31 04:37 PM
Lafond Kevin GSVP, Treasurer & CAONov 26Option Exercise2.8511,66733,25197,222Nov 27 05:07 PM
Lafond Kevin GSVP, Treasurer & CAONov 26Sale5.2511,66761,25285,555Nov 27 05:07 PM